Related Experiment Videos
Radioiodine therapy for differentiated thyroid carcinoma
C S Connor1, J H Thomas, R G Robinson
1Department of General Surgery, University of Kansas Medical Center, Kansas City 66103.
American Journal of Surgery
|December 1, 1988
Summary
Adjuvant radioiodine (iodine 131) therapy is an underutilized treatment for differentiated thyroid carcinoma. This study shows it effectively detects and treats metastatic disease, supporting its more frequent use.
Area of Science:
- Endocrinology
- Nuclear Medicine
- Oncology
Background:
- Differentiated thyroid carcinoma (DTC) management often includes adjuvant therapy.
- Radioiodine (iodine 131) is a recognized treatment but is frequently underutilized.
- Assessing its role in routine DTC management is crucial.
Purpose of the Study:
- To evaluate the effectiveness of adjuvant radioiodine (iodine 131) therapy in differentiated thyroid carcinoma.
- To determine the incidence of metastasis detected by iodine-131 scans.
- To assess treatment response in patients with metastatic disease.
Main Methods:
- Retrospective review of 29 patients receiving adjuvant iodine 131 therapy over a 2-year period.
- Utilized iodine-131 scans to identify local or distant metastasis.
- Compared scan findings with operative findings and chest radiography.
Main Results:
- Iodine-131 scans detected metastasis in 35% of patients.
- Unsuspected metastatic lesions were identified in 24% of patients.
- Complete response to therapy was achieved in 70% of patients with metastatic disease.
Conclusions:
- Adjuvant radioiodine therapy is effective in detecting and treating metastatic differentiated thyroid carcinoma.
- The study supports increased utilization of iodine 131 in DTC management.
- Radioiodine therapy offers a significant benefit for patients with metastatic disease.